title: [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
abstract: Sibutramine and Orlistat are suitable "supporting drugs" for use in patients trying to lose weight. Orlistat reduces the absorption of fat from the intestine by about one-third. Over the long term too, the weight loss achieved under Orlistat (9%) has been greater than that seen under placebo (6.5%). Increased fat losses via the stools are associated with side effects and abandonment of treatment. Sibutramine inhibits the uptake of serotonin and noradrenaline in the synaptic gap, thus enhancing the CNS effects of these two transmitters, and prolonging the sensation of satiety. The most common side effects of sibutramine are dry mouth, headache and fatigue. The effects of sibutramine on weight reduction are similar to those of orlistat. For both drugs, the indications have been defined, and in the case of sibutramine, interactions with other medications have to be taken into account.
authors.affiliation: Institut für Fettstoffwechsel und Hämorheologie, Windach/Ammersee. ifn-richter@t-online.de
authors.forename: W O
authors.initials: WO
authors.lastname: Richter
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000075202:Contraindications; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D016896:Treatment Outcome
chemical_list: D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; D007783:Lactones; D000077403:Orlistat; C058254:sibutramine